Business context and reporting period
The supplied filing is Isoray, Inc.’s Form 10-Q for the quarter ended December 31, 2018 (fiscal 2019 second quarter), not a filing for Perspective Therapeutics. Isoray manufactures and sells Cesium-131 brachytherapy seeds. Unless noted otherwise, financial figures below are in millions of dollars.
Financial performance and liquidity
- Quarter revenue: $1.904, up 24% from $1.536 a year earlier. Prostate brachytherapy sales were $1.695, up 29%; other brachytherapy sales were $0.209, down 5%.
- Six-month revenue: $3.466, up 26% from $2.747.
- Gross profit and margin: Quarterly gross profit was $0.765, with a 40.2% margin versus $0.531 and 34.6% a year earlier. Six-month gross profit was $1.289, with a 37% margin versus $0.796 and 29%.
- Operating expenses and losses: Quarterly operating expenses were $2.194, up 10%; operating loss was $1.429 versus $1.468. Net loss was $1.414 versus $1.463, and loss per share was $0.02 versus $0.03. For six months, operating loss was $2.947 and net loss was $2.922, compared with $3.020 and $3.010, respectively.
- Cash flow: Six-month operating cash use was $2.726, compared with $3.184 a year earlier. Investing cash use was $4.043; financing provided $7.370, primarily from the July 2018 stock offering. Cash, cash equivalents, and restricted cash increased $0.601.
- Liquidity and debt: At December 31, cash and cash equivalents were $3.201 and short-term investments were $4.667. Working capital was $8.180 and the current ratio was 5.99. Total liabilities were $2.246, including a $0.606 asset retirement obligation; the balance sheet reports no borrowings.
Material changes and notable developments
- The July 2018 registered direct offering sold 11 million shares for $8.25 million gross proceeds and approximately $7.38 million net proceeds. It also included warrants covering 5.83 million shares; cash proceeds from warrant exercises are conditional on exercise.
- Quarterly sales growth and operating efficiencies lifted gross margin, while operating expenses increased, including research and development and general and administrative costs.
- The company reported a limited market release of its Blu Build delivery system in late October 2018. It completed design transfer to production for the GammaTile collaboration at the end of December.
- The company terminated its University of Missouri Research Reactor irradiation services agreement in December. Management estimated that alternative sourcing could save approximately $0.45 million annually if isotope purchases remain constant, but gave no assurance of achieving the savings.
Outlook, risks, and contingencies
- Management’s fiscal 2019 target was revenue growth of 25%; it said first-half growth exceeded that target. Assuming continued growth and no extraordinary expenses, management estimated cash-flow break-even in three to five years. These are conditional expectations, not assured results.
- Management said the July financing meant it did not anticipate needing additional capital to finance operations for the next fiscal year. It also stated future needs may be funded through equity, strategic collaborations, debt, or other sources, potentially dilutive to shareholders.
- Cesium-131 supply remains a key risk. The Russian supply agreement was extended through December 31, 2019; current pricing and volumes apply through May 31, 2019, with later pricing subject to renegotiation. Reactor shutdowns mean only one of the company’s historic Russian suppliers would be available during specified periods. The company also disclosed uncertainty around future supply from its enriched-barium consignment arrangement.
- Customer concentration is material: five customers represented approximately 45% of six-month revenue, with one accounting for approximately 22%. Management warned that losing a major customer could materially harm revenue.
- Other brachytherapy sales can fluctuate because applications depend on a small group of early-adopting physicians. The filing reports no legal proceedings and no material changes to previously disclosed risk factors other than customer concentration.
Important facts for investors to verify
- Confirm the issuer and period: the supplied filing is for Isoray, Inc., quarter ended December 31, 2018, despite the request metadata naming Perspective Therapeutics and 2018 Q2.
- Track Cesium-131 supply continuity, pricing after May 31, 2019, and execution of alternative sourcing and the estimated cost savings.
- Assess whether revenue growth, gross-margin gains, and the stated fiscal 2019 growth target persist, and how they affect cash burn and the conditional break-even timeline.
- Monitor dependence on the five largest customers and the potential dilution from outstanding warrants or future financing.
- Evaluate the planned production automation investment: approximately $0.697 million had been invested through December 31, with about $0.215 million more expected over the following nine months.